PILL:NYE-Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 7.63

Change

+0.04 (+0.53)%

Market Cap

N/A

Volume

0.09M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-25 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B..

-1.69 (-6.32%)

USD 9.27B
QLD ProShares Ultra QQQ

-2.80 (-2.54%)

USD 8.27B
FNGU MicroSectors FANG+ Index 3X Le..

-24.22 (-4.33%)

USD 8.18B
SSO ProShares Ultra S&P500

-0.96 (-1.01%)

USD 5.76B
UPRO ProShares UltraPro S&P500

-1.45 (-1.58%)

USD 4.34B
TECL Direxion Daily Technology Bull..

-3.32 (-3.88%)

USD 3.09B
YINN Direxion Daily FTSE China Bull..

+1.28 (+3.17%)

USD 1.89B
USD ProShares Ultra Semiconductors

-2.87 (-4.88%)

USD 1.16B
UDOW ProShares UltraPro Dow30

+1.06 (+1.07%)

USD 0.77B
LABU Direxion Daily S&P Biotech Bul..

-4.10 (-4.73%)

USD 0.77B

ETFs Containing PILL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.46% 57% F 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.46% 57% F 84% B
Trailing 12 Months  
Capital Gain -21.42% 12% F 11% F
Dividend Return 0.80% 37% F 11% F
Total Return -20.62% 12% F 10% F
Trailing 5 Years  
Capital Gain -58.99% 18% F 7% C-
Dividend Return 1.51% 16% F 4% F
Total Return -57.49% 17% F 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 57.25% 79% B- 94% A
Dividend Return 57.83% 79% B- 94% A
Total Return 0.59% 41% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 392.98% 15% F 3% F
Risk Adjusted Return 14.72% 27% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.